The Oncomine database showed that ANXA1 mRNA expression was downregulated in ovarian cancer, while both of the databases showed that ANXA3 and ANXA11 mRNA expression levels were significantly upregulated in ovarian cancer, among which the upregulation of ANXA11 mRNA displayed a significant correlation with poor PFS in patients with ovarian serous tumors. This evidence concerns the gene ANXA3 and ovarian serous tumor.